Limin Zheng joined GCA Law Partners LLP as a litigation partner in 2017. She specializes in patent and other intellectual property litigation. Before joining GCA, Dr. Zheng was a litigation principal at Fish & Richardson P.C., where she practiced patent and other complex technology litigation for over a decade.
Dr. Zheng has hands-on experience in all stages of litigation, including trial, involving a broad range of technologies. She has litigated in numerous forums, including federal district courts, the International Trade Commission, and the Patent Trial and Appeal Board. In addition to litigating in court and administrative proceedings, Dr. Zheng counsels and works with clients on litigation strategy and management, dispute avoidance, and alternative dispute resolution. She also advises U.S. clients on patent litigation in China.
A native of Shanghai, Dr. Zheng is fluent in Mandarin Chinese.
Dr. Zheng holds a J.D. from University of California, Berkeley School of Law, where she served on the Editorial Board of the California Law Review and as an annual review advisor for the Berkeley Technology Law Journal. While in law school, Dr. Zheng served as legal extern to the Honorable Claudia Wilken and the Honorable D. Lowell Jensen, United States District Court Judges with the Northern District of California.
Before starting her legal career, Limin earned her Ph.D. from University of Pittsburgh, where she studied and conducted research in molecular and developmental biology. She conducted her postdoctoral research at Stanford University, School of Medicine, where she was a Fellow of the Jane Coffin Childs Memorial Fund for Medical Research.
Dr. Zheng is admitted to practice in California, all U.S. District Courts in California, U.S. District Court for the Eastern District of Texas, U.S. Court of Appeals for the Ninth Circuit, and U.S. Court of Appeals for the Federal Circuit. In addition, Dr. Zheng serves as a mediator on the ADR Neutral Panel of the U.S. District Court for the Northern District of California.
- How Will Trump’s New FTC/DOJ Reporting Requirements Impact Biosimilars?, Biosimilar Development (Nov. 13, 2018)
- A Biosimilar Applicant’s (Illusory?) Right To Declaratory Relief, Biosimilar Development (Aug. 9, 2018)
- Recent Supreme Court Decisions On Inter Partes Review — What Biosimilar Developers Need To Know, Bioprocess Online (May 22, 2018)
- Shall We (Patent) Dance? — Key Considerations For Biosimilar Applicants, Biosimilar Development (Feb. 27, 2018)
- The Biosimilar Patent Dance: What Can We Learn From Recent BPCIA Litigation?, Biosimilar Development (Mar. 6, 2018)
- The Post-Mayo World Of Life Sciences Patents (Part 1; Part 2; Part 3), Biosimilar Development (December 2017 – January 2018)
- The Biosimilar Patent Dance: When in Doubt, List It, Daily Journal (August 16, 2017)
- What the Numbers Tell Us About the Section 101 ‘Fad’, Recorder (Mar. 2017)
- Comment, Actual Innocence As a Gateway Through the Statute-of-Limitations Bar on the Filing of Federal Habeas Corpus Petitions, 90 CALIF. L. REV. 2101 (2002)
- Note, Purdue Pharma L.P. v. Faulding Inc., 17 BERKELEY TECH. L.J. 95 (2002)
- Zheng also has numerous scientific publications directed to her doctoral and postdoctoral research studying molecular signaling pathways in early development using Drosophila as a model system